Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
HUTCHMED (00013.HK) Sovleplenib NDA Accepted and Granted Priority Review
Recommend 12 Positive 16 Negative 11 |
||||
|
||||
|
HUTCHMED (00013.HK) announced that the New Drug Application (NDA) for sovleplenib for the treatment of adult patients with warm antibody autoimmune hemolytic anemia who have had an inadequate response to at least one prior line of glucocorticoid therapy has been accepted by the China National Medical Products Administration and has been granted priority review. Sovleplenib is a novel, highly selective oral spleen tyrosine kinase (SYK) inhibitor being developed for the treatment of autoimmune diseases and hematological malignancies. (de/d) Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
